Alkylating agents showed no clear difference in chlorambucil: leucopenia compared with steroids, placebo or both; GRADE not reported.
Rituximab may leads to higher adverse effects: moderate to severe Infusion reactions compared with placebo or control (low certainty).
Rituximab showed no clear difference in adverse effects: severe infection compared with placebo or control (low certainty).
Rituximab showed no clear difference in adverse effects: arthropathy compared with placebo or control (low certainty).
Intravenous immunoglobulin showed no clear difference in death compared with placebo (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Intravenous immunoglobulin may leads to higher response at 3 months compared with placebo (low certainty).
Intravenous immunoglobulin showed no clear difference in relapse at 3 months compared with placebo (low certainty).
Intravenous immunoglobulin may leads to higher adverse events compared with placebo (low certainty).
The review found no eligible studies for this question.
Antibiotics showed no clear difference in death at 6 months compared with placebo (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Antibiotics showed no clear difference in remission at one year compared with placebo (low certainty).
The review found no eligible studies for this question.
Antibiotics showed no clear difference in adverse events causing study drug discontinuation compared with placebo (low certainty).
Antibiotics may leads to lower infection (urinary tract infection) compared with placebo (low certainty).
It is very uncertain whether aldosterone antagonists changes kidney failure compared with placebo or standard care (very low certainty).
Aldosterone antagonists probably leads to higher hyperkalaemia compared with placebo or standard care (moderate certainty).